3-(4-(Piperidin-1-ylmethyl)phenyl)-9H-pyrrolo[2,3-b:5,4-c']dipyridine-6-carbonitrile
Completing data — refresh the page later to see the latest
Basic information
- CAS
1200126-26-6- Standard SMILES
N#Cc1cc2c(cn1)[nH]c1ncc(-c3ccc(CN4CCCCC4)cc3)cc12- InChIKey
PPYHOOZGDDPLKM-UHFFFAOYSA-N- Molecular formula
- C23H21N5
- Average molar mass
- 367.4 g/mol
- Monoisotopic mass
- 367.17969569
Names & identifiers
- Preferred name
- 3-(4-(Piperidin-1-ylmethyl)phenyl)-9H-pyrrolo[2,3-b:5,4-c']dipyridine-6-carbonitrile
- IUPAC
- 12-[4-(piperidin-1-ylmethyl)phenyl]-5,8,10-triazatricyclo[7.4.0.02,7]trideca-1(9),2(7),3,5,10,12-hexaene-4-carbonitrile
- English name
- GNE 900
- Molecular formula
- C23H21N5
- Molecular weight
- 367.45
Names & synonyms
1200126-26-6GNE-9003-(4-(Piperidin-1-ylmethyl)phenyl)-9H-pyrrolo[2,3-b:5,4-c']dipyridine-6-carbonitrile3-[4-(Piperidin-1-Ylmethyl)phenyl]-9h-Pyrrolo[2,3-B:5,4-C']dipyridine-6-CarbonitrileCHEMBL358220112-[4-(piperidin-1-ylmethyl)phenyl]-5,8,10-triazatricyclo[7.4.0.02,7]trideca-1(9),2(7),3,5,10,12-hexaene-4-carbonitrileGNE 900PPYHOOZGDDPLKM-UHFFFAOYSA-Norb1738221SCHEMBL1889376SCHEMBL29374959AYB12626
Show more names
GNE9009H-Pyrrolo[2,3-b:5,4-c']dipyridine-6-carbonitrile, 3-[4-(1-piperidinylmethyl)phenyl]-
EX-A7838BDBM50091293EBC-509249DA-63852GNE-900, >98% (HPLC)HY-15883TS-09586CS-0009456
Database identifiers
- CAS
1200126-26-6- PubChem CID
- 44545757
Properties
Computed structural propertiesFilling in
- XLogP
- 3.9
- Topological polar surface area
- 68.6 Ų
- Hydrogen bond donors
- 1
- Hydrogen bond acceptors
- 4
- Rotatable bonds
- 3
- Heavy atoms
- 28
- Formal charge
- 0
- Complexity
- 571
Physicochemical properties
- form
- Solid
- color
- Light yellow to brown
Chemistry & industry
Applications
DescriptionGNE-900 is an ATP-competitive, selective, and orally bioavailable ChK1 inhibitor. In combination with chemotherapeutic agents, GNE-900 sustains ATR/ATM signaling, enhances DNA damage, and induces apoptotic cell death. GNE-900 has little single-agent activity in the absence of chemotherapy and does not grossly potentiate the cytotoxicity of gemcitabine in normal bone marrow cells. In vivo scheduling studies show that optimal administration of the ChK1 inhibitor requires a defined lag between gemcitabine and GNE-900 administration. (Mol Cancer Ther; 12(10); 1968-80).
UsesGNE-900 is a an ATP-competitive, selective, and orally active ChK1 inhibitor with IC50s of 0.0011, 1.5 μM for ChKl, ChK2, respectively. GNE-900 abrogates the G2-M checkpoint, enhances DNA damage, and induces Apoptosis. gemcitabine (HY-17026) and GNE-900 administration shows anti-tumor activity[1].
Related reactions
2 records
Compound notes
Loading…